Committee to Restore Nymox Shareholder Value Challenges Nymox CEO Averback to Publish 2022 FDA Refusal To File Correspondence Received May 10, 2022

[#item_full_content]CARSON CITY, Nev. & LONDON–(BUSINESS WIRE)–Committee to Restore Nymox Shareholder Value Challenges Nymox CEO Averback to Publish 2022 FDA Refusal To File Correspondence Received May 10, 2022